Re-Certification Achieved: C-RAY Enhances Radiopharmaceutical Transport Capabilities

C RAY NEWS

 

 

 

C-RAY has achieved a breakthrough in ​​radiopharmaceutical supply chain optimization​​ by obtaining China’s ​​Radioactive Pharmaceutical Road Transport License​​. The company now operates a ​​comprehensive transport network (road + air)​​, ​​reducing logistics costs for partners​​ and enabling ​​broader collaboration with research institutions​​.

 

 

 

 

Radiopharmaceutical Supply Chain Capabilities

 

C-RAY engineered ​​proprietary radioactive packaging systems​​ that passed ​​rigorous safety tests​​ (drop, puncture, and seal integrity) compliant with ​​Sichuan Airlines’ air cargo standards​​. The ​​hybrid ground-air transport model​​ ensures ​​flexible and reliable delivery​​ across diverse scenarios.

 

Two ​​C-RAY-designed containers​​ with ​​full IP ownership​​ have been validated by ​​third-party laboratories​​, meeting:
• ​​GB 11806​​ 
• ​​IAEA SSR-6​​
• ​​IATA DGR​​ 

 

​​• 24–48h delivery to 90% of China’s population centers​​

​​• 72h APAC-wide coverage​;

 

C-RAY’s ​​advanced cold chain logistics​​ not only ensure ​​time-sensitive delivery​​ and ​​expanded coverage​​ but also ​​significantly reduce transport costs through operational efficiencies

 

The widespread adoption of ​​novel radiopharmaceuticals​​ relies on a ​​synergistic ecosystem​​ — particularly in this field, where ​​seamless integration of R&D, production, and distribution​​ is critical to achieving efficient cycles.​​.

 

The ​​interconnected chain of manufacturing, quality control (QC), and distribution​​ poses challenges not only to ​​C-RAY’s operations​​ but also to the ​​sustainable growth of China’s radiopharmaceutical sector​​.

 

C-RAY believes this ​​supply chain advancement​​ not only ​​elevates its service capabilities​​ but also ​​catalyzes a mature industry ecosystem through collaborative partnerships​​.

 
 
 

 

C-RAY’s ​​enhanced cold chain logistics​​ enable ​​broader distribution of radiopharmaceutical solutions​​ to partners and research institutions. Since launching ​​radiopharmaceutical R&D and manufacturing services​​, the company has achieved:
✅ ​​1 IND approval​
✅ ​​3 INDs in active preclinical development​
✅ ​​14 pipeline projects in research phase​

 

In the future, C-RAY will ​​strengthen its platform infrastructure and service capabilities​​, ​​empowering deep R&D in the radiopharmaceutical field​​. Through ​​collaborative partnerships with upstream and downstream enterprises​​, the company aims to collectively navigate the ​​blue ocean of the radiopharmaceutical industry​​.

 

 

Created on:2025-04-25

hot news